Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia
Authors:
- 1 August 2015
- journal article
- Published by Elsevier in Physiology & Behavior
- Vol. 147, 193-197
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology (2013ZX09102-017)
- Doctoral Foundation of Yantai University (YX12B30, SM12B19)
- Taishan Scholar Project
This publication has 26 references indexed in Scilit:
- Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of l-dopa by normalizing Parkinson's disease-induced neurochemical imbalanceBrain Research, 2014
- The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesiaBehavioural Pharmacology, 2013
- Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in ratsEuropean Journal of Pharmacology, 2013
- l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's diseaseNeurobiology of Aging, 2010
- Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than womenEuropean Journal of Neurology, 2010
- Effects of Hydroxysafflor Yellow A in the Attenuation of MPTP Neurotoxicity in MiceNeurochemical Research, 2009
- Pharmacological validation of a mouse model of l-DOPA-induced dyskinesiaExperimental Neurology, 2005
- Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian ratsExperimental Neurology, 2005
- “Levodopa phobia”: A new iatrogenic cause of disability in Parkinson diseaseNeurology, 2005
- The New Face of Traditional Chinese MedicineScience, 2003